AstraZeneca announced plans to invest $50 billion in expanding its manufacturing and research capabilities in the U.S. by 2030. This investment includes a new drug manufacturing facility in Virginia and expansion of research and development, as well as cell therapy manufacturing across multiple states. The initiative supports AstraZeneca’s goal to reach $80 billion in annual revenue by 2030, with half of that revenue coming from the U.S. The move is in response to tariff policies aimed at boosting domestic production of pharmaceuticals.
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, responding to President Trump's tariff policy.
The investment will fund a new drug manufacturing facility in Virginia and expand R&D and cell therapy manufacturing across several states.
AstraZeneca aims to achieve $80 billion in annual revenue by 2030, with half coming from the U.S., which is a prioritized market for the company.
CEO Pascal Soriot emphasized that the U.S. cannot solely fund global R&D costs, indicating a need for price equalization among countries.
Collection
[
|
...
]